| CereVasc Opens New Massachusetts Facility in Preparation for eShunt® System Commercialization New facility expands production and R&D capabilities following completion of STRIDE Clinical Trial enrollment and recent $85 million Series C financing • Wilmington facility includes an ISO Class 7 clean room supporting assembly, inspection, testing and manufacturing operations for the investigational eShunt System […] The post CereVasc Opens New Massachusetts Facility in Preparation for eShunt® System Commercialization appeared first on CereVasc |
Neurological Disease Device Company . |
